# An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

> **NCT05025241** · PHASE2 · COMPLETED · sponsor: **Neuren Pharmaceuticals Limited** · enrollment: 18 (actual)

## Conditions studied

- Phelan-McDermid Syndrome

## Interventions

- **DRUG:** NNZ-2591

## Key facts

- **NCT ID:** NCT05025241
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-08
- **Primary completion:** 2023-11-01
- **Final completion:** 2023-11-17
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025241, "An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05025241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*